Wound Management Technologies Exhibits at Premier International Diabetic Foot Conferenc...( -- Accepted Abstract on CellerateRx C...),Health

-- Accepted Abstract on CellerateRx Conducted by Dr. Matt Regulski --

FORT WORTH, Texas, March 20 /PRNewswire-FirstCall/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), announced today that it is exhibiting at DFCon 09 on March 19-21, 2009 at the Renaissance Hollywood Hotel in Los Angeles, California. DFCon is considered the premier international multidisciplinary diabetic foot conference that attracts attendees from more than 50 foreign countries and all 50 U.S. states.

One of the DFCon 09's accepted abstracts this year is Activated Collagen: An Evidence Based Study (Interim Data) in Human Leg Ulcers. This abstract features Wound Care Innovations' advanced wound care collagen gel CellerateRx(R) and was conducted by Dr. Matt Regulski, Director of Wound Care Center of Ocean County, NJ. Dr. Regulski graduated Summa Cum Laude from Temple University. He is Board-certified in wound care, an associate of the American College of Foot and Ankle Surgeons (ACFAS) and a partner of the Ocean County Foot and Ankle Surgery Association. He has published several wound care papers and is a frequent speaker at medical conferences.

Dr. Regulski commented, "The initial data shows that CellerateRx treated wounds were healed by six (6) weeks and the control wounds were approximately 60% healed at fourteen (14) weeks," said Dr. Matt Regulski. "I was impressed by the speed and efficacy of CellerateRx. Diabetic ulcers remain one of the biggest problems and challenges that we face in healthcare today, both in terms of economic expenditures and patient welfare. Most amputations begin with an ulcer, so having a product that can help manage these wounds more effectively will save limbs and resources." A copy of the abstract is available online at www.Celleraterx.com.

"Dr. Regulski
'/>"/>